Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DLAT | P10515 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269968 | 0.64 | ALOX5 (0.41) | ACHEALOX5PTGESNR1I2CYP3A4 | |
| SCHEMBL30211331 | 0.63 | ALOX5 (0.43) | ACHEALOX5PTGESNR1I2CYP3A4 | |
| SCHEMBL29957759 | 0.60 | KDM4E (0.32) | ALOX5PTGESNR1I2CYP3A4DLAT | |
| SCHEMBL13649117 | 0.58 | ALOX5 (0.55) | ACHEALOX5PTGESNR1I2CYP3A4 | |
| SCHEMBL13629032 | 0.58 | ALOX5 (0.41) | ACHEALOX5PTGESNR1I2CYP3A4 | |
| SCHEMBL823105 | 0.57 | ALOX5 (0.40) | ACHEALOX5 | |
| SCHEMBL7896034 | 0.57 | KDM4E (0.35) | ALOX5PTGESNR1I2CYP3A4DLAT | |
| SCHEMBL30834770 | 0.56 | LMNA (0.33) | CYP3A4SMN1; SMN2 | |
| SCHEMBL13649105 | 0.56 | SLC25A5 (0.35) | ACHEALOX5PTGESNR1I2CYP3A4 | |
| SCHEMBL2442779 | 0.56 | ALOX5 (0.38) | ACHEALOX5PTGESNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346552-A1 | PRECURSOR COMPOUND OF HEXAHYDRO-BETA-ACID COMPONENT COMPOUND, FEED COMPOSITION AND USE THEREOF | WISORIG TECHNOLOGIES PTE. LIMITED (SG) | 2025-11-13 | — | — | US | disclosed |
| US-12133541-B2 | Feed composition comprising hexahydro-β-acid component compounds and application thereof | WISORIG TECHNOLOGIES PTE. LIMITED (SG) | 2024-11-05 | — | — | US | disclosed |
| US-20220232856-A1 | FEED COMPOSITION COMPRISING HEXAHYDRO-beta-ACID COMPONENT COMPOUNDS AND APPLICATION THEREOF | WISORIG TECHNOLOGIES PTE. LIMITED (SG) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346552-A1 | PRECURSOR COMPOUND OF HEXAHYDRO-BETA-ACID COMPONENT COMPOUND, FEED COMPOSITION AND USE THEREOF | HCAR3, FFAR3, HCAR2 | ACHE 2512/4885ALOX5 389/4885PTGES 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.